Cytokinetics
Corporate brand
UnclaimedA biopharmaceutical company developing muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
Last updated August 22, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Cytokinetics, Incorporated, is a South San Francisco biopharmaceutical company focused on the biology and mechanics of muscle. Its research platform examines how molecular components of muscle, including actin, myosin, troponin and related contractile machinery, can be modulated to improve or restrain muscle performance. The company develops small-molecule muscle activators and inhibitors as potential treatments for diseases in which muscle function is impaired, declining or abnormally increased. The company was founded in 1997 by scientists James Spudich, Ronald Vale, James Sabry and Lawrence S. B. Goldstein, whose academic backgrounds included Stanford University, the University of California, San Diego, and the University of California, San Francisco. Cytokinetics began operations in 1998. Its early work explored pharmacological targets associated with cytoskeletal proteins and possible therapeutic applications. Over time, the company narrowed its strategy toward muscle biology, especially the molecular mechanisms governing cardiac and skeletal-muscle contraction. Cytokinetics became a publicly traded company through an initial public offering in 2004. Its development portfolio subsequently centered on cardiovascular and neuromuscular indications. A major early collaboration was established with Amgen around omecamtiv mecarbil, a cardiac myosin activator intended to improve cardiac contractility in heart failure. Cytokinetics and Amgen expanded the relationship to Japan in 2013, but Amgen later elected to end the collaboration, with termination effective in May 2021. Cytokinetics consequently regained worldwide development and commercialization rights to the program. The company has also advanced skeletal-muscle and cardiac-muscle programs. Reldesemtiv, formerly known as CK-2127107, is a fast skeletal-muscle troponin activator investigated for conditions including amyotrophic lateral sclerosis. Aficamten, formerly known as CK-3773274, is an oral small-molecule cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, a disease characterized by excessive thickening of the heart muscle. In 2020, Cytokinetics entered a financing and regional commercialization arrangement with Ji Xing Pharmaceuticals covering aficamten in China and certain neighboring territories. Cytokinetics' business model is research- and development-led. Its principal offerings are investigational medicines rather than established consumer products, and the company relies on laboratory research, clinical development, regulatory review, licensing transactions and strategic partnerships. Its positioning is based on specialization in muscle contractility and the cytoskeleton rather than on a broad multi-therapeutic pharmaceutical portfolio. The company remains active and publicly listed under the ticker CYTK, with cardiovascular and neuromuscular muscle disorders as its principal areas of focus.
History
Cytokinetics was established in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S. B. Goldstein. The founders were scientists associated with Stanford University and the University of California system, bringing academic expertise in molecular motors, cytoskeletal proteins and cellular biology. The company began operations in 1998 and was created to translate knowledge about the cytoskeleton into pharmacological approaches for serious disease. During its early period, Cytokinetics considered a range of potential drug targets and applications involving cytoskeletal proteins. Its research strategy later became more focused. Rather than pursuing the cytoskeleton as a broad biological category, the company concentrated on the mechanics of muscle, including the molecular events that control cardiac and skeletal-muscle contraction. This specialization led to a platform based on compounds that could either activate or inhibit components of the contractile apparatus. Cytokinetics completed its initial public offering in 2004. As a public biotechnology company, it continued to advance discovery and clinical programs while using collaborations to support development and commercialization. In 2006, Amgen obtained an option relating to omecamtiv mecarbil, a cardiac muscle activator developed for heart failure. The relationship was extended on multiple occasions, reflecting the importance of the program to Cytokinetics' cardiovascular strategy. In 2013, the companies expanded their licensing arrangement to include Japan. In January 2007, Robert I. Blum became president and chief executive officer. Blum had been involved with Cytokinetics since its founding and had previously held responsibilities in business development, corporate development and research and development. His appointment represented continuity between the company's scientific origins and its increasingly partnership-oriented public-company structure. The company broadened its muscle-focused pipeline beyond cardiac activation. Reldesemtiv, previously identified as CK-2127107, was developed as a next-generation fast skeletal-muscle troponin activator. The program entered clinical testing for neuromuscular conditions, including amyotrophic lateral sclerosis. Cytokinetics also pursued aficamten, formerly designated CK-3773274, an oral small-molecule myosin inhibitor intended to address hypertrophic cardiomyopathy. This program represented a complementary approach to omecamtiv mecarbil: instead of increasing cardiac contractile activity, aficamten was designed to reduce excessive contractility associated with certain forms of cardiac muscle disease. In 2013, Cytokinetics finalized a licensing and discovery agreement with Astellas to research treatments for muscle weakness and fatigue. The arrangement reflected the company's continuing use of external partnerships to explore applications of its muscle-biology platform. In July 2020, Cytokinetics entered a financing arrangement with Ji Xing Pharmaceuticals covering aficamten rights in China and certain neighboring regions, giving the program a regional development and commercialization pathway. Another major turning point came in November 2020, when Amgen elected to terminate its omecamtiv mecarbil collaboration. The termination became effective on May 20, 2021, after which Cytokinetics regained worldwide development and commercialization rights. The change returned control of the program to its original developer and increased Cytokinetics' responsibility for the medicine's subsequent development and potential commercialization. By the period described in the available reference material, Cytokinetics remained an active, publicly listed biopharmaceutical company headquartered in South San Francisco. Its identity continued to rest on muscle biology: developing activators and inhibitors for diseases involving declining, impaired or excessive muscle function. Its principal therapeutic interests were cardiovascular and neuromuscular disorders, and its principal assets remained investigational rather than established consumer products.
- 2021
Cytokinetics regains worldwide omecamtiv mecarbil rights
[1]Amgen's termination of the collaboration became effective on May 20, 2021, returning worldwide development and commercialization rights to Cytokinetics.
- 2020
Omecamtiv mecarbil receives FDA Fast Track designation
[1]The FDA granted Fast Track designation for potential treatment of chronic heart failure with reduced ejection fraction.
- 2020
Ji Xing arrangement for aficamten
[1]Ji Xing Pharmaceuticals entered a financing arrangement that included regional commercialization rights for aficamten in China and certain neighboring markets.
- 2013
Astellas research and discovery agreement
[1]Cytokinetics finalized a licensing and discovery deal with Astellas focused on treatments for muscle weakness and fatigue.
- 2013
Amgen collaboration expands to Japan
[1]The companies expanded their omecamtiv mecarbil licensing arrangement to include Japan.
- 2007
Robert I. Blum becomes president and CEO
[1]Robert I. Blum was appointed president and chief executive officer after earlier work with the company in business development, corporate development and research and development.
- 2006
Amgen obtains an option on omecamtiv mecarbil
[1]Amgen purchased an option relating to the cardiac muscle activator omecamtiv mecarbil.
- 2004
Initial public offering
[1]The company completed its initial public offering.
- 1998
Operations begin
[1]Cytokinetics began operating as a company focused initially on cytoskeletal biology and pharmacological targets.
- 1997
Cytokinetics is founded
[1]James Spudich, Ronald Vale, James Sabry and Lawrence S. B. Goldstein founded the company.
Products and positioning
A specialist biopharmaceutical company focused on muscle biology, contractility and cytoskeletal mechanisms, with development programs targeting cardiovascular and neuromuscular diseases.
Cardiac muscle activator
Omecamtiv mecarbil
Omecamtiv mecarbil is an investigational cardiac muscle activator designed to affect the mechanics of cardiac contraction. Cytokinetics developed it as a potential treatment for heart failure, including chronic heart failure with reduced ejection fraction. Amgen obtained an option on the program in 2006, and the collaboration was expanded to Japan in 2013. Amgen later elected to terminate the collaboration, effective May 20, 2021, after which Cytokinetics regained worldwide development and commercialization rights. The FDA granted the program Fast Track designation in May 2020.
Fast skeletal-muscle troponin activator
Reldesemtiv
Reldesemtiv, previously known as CK-2127107, is a next-generation fast skeletal-muscle troponin activator. The compound was designed to increase the responsiveness of skeletal-muscle contractile machinery and was evaluated in clinical studies for neuromuscular diseases, including amyotrophic lateral sclerosis. It represents Cytokinetics' effort to apply its muscle-biology platform beyond cardiac muscle and to conditions characterized by weakness or declining skeletal-muscle function.
Cardiac myosin inhibitor
Aficamten
Aficamten, previously known as CK-3773274, is an oral small-molecule cardiac myosin inhibitor developed for hypertrophic cardiomyopathy. Its mechanism is intended to moderate excessive cardiac contractility associated with the disease. In 2020, Cytokinetics entered a financing and regional commercialization arrangement with Ji Xing Pharmaceuticals that included rights covering China and certain neighboring regions. Aficamten is one of the company's principal cardiac-muscle development programs.
Brand decisions
2020
Cytokinetics establishes a regional aficamten arrangement with Ji Xing PharmaceuticalsStrategyBackground
Cytokinetics was developing aficamten for hypertrophic cardiomyopathy and sought regional financing and commercialization support.
Action taken
Ji Xing Pharmaceuticals signed a financing arrangement that included rights to commercialize aficamten in China and certain neighboring regions.
Aftermath
The transaction created a regional pathway for development and potential commercialization of aficamten.
2020
Cytokinetics prepares to resume worldwide control of omecamtiv mecarbilStrategyBackground
Amgen had been collaborating with Cytokinetics on the cardiac muscle activator since obtaining an option in 2006.
Action taken
Amgen elected to terminate the collaboration, with termination scheduled to become effective on May 20, 2021.
Aftermath
Cytokinetics regained worldwide development and commercialization rights to omecamtiv mecarbil.
2013
Cytokinetics enters an Astellas licensing and discovery agreementStrategyBackground
The company was expanding its muscle-biology platform toward treatments for weakness and fatigue.
Action taken
Cytokinetics finalized a licensing and discovery deal with Astellas to research potential treatments for muscle weakness and fatigue.
Aftermath
The agreement added a strategic research partner to Cytokinetics' muscle-focused development activities.
2006
Cytokinetics grants Amgen an option relating to omecamtiv mecarbilM&ABackground
Cytokinetics sought external support for development of its cardiac muscle activator program.
Action taken
Amgen purchased an option on omecamtiv mecarbil, beginning a collaboration that was later extended.
Aftermath
The collaboration was expanded to Japan in 2013 and ultimately terminated in 2021, when Cytokinetics regained worldwide rights.
Recent events
Reported
Amgen terminates collaboration with Cytokinetics[3]
Cytokinetics said Amgen elected to terminate their collaboration, effective May 20, 2021.
Reported
Cytokinetics announces grant and partnership with HCM Registry[4]
Cytokinetics announced a $1 million grant and a four-year partnership with the HCM Registry, which focuses on improving prediction of risk and outcomes in hypertrophic cardiomyopathy.
Reported
Jenscare licenses CK-274 rights for Greater China[5]
Jenscare and Cytokinetics signed an exclusive license agreement for the development and commercialization of CK-274 in Greater China. Jenscare committed to an upfront payment, up to an additional $200 million in development and commercialization milestone payments, and royalties on sales in the licensed territory.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/cytokinetics · Editorial policy · How profiles are compiled